Pharmaceutical packaging comprising a chemically resistant glass

1. A pharmaceutical packaging comprising:

a container made of a glass, said glass comprising at least the following components (given in mol % on oxide basis):

SiO 2

59-84

Al 2 O 3

  7-18.5

CaO

 1-25

SrO

  0-6.5

BaO

0-5

ZrO 2

0.5-3  

TiO 2

0-5

B 2 O 3

 0-1,

wherein said glass comprise a ratio (CaO+SrO+BaO)/Al 2 O 3 <2.8;

wherein said glass comprises a ratio (CaO+SrO+BaO)/SiO 2 ≤0.39;

wherein said glass comprises a hydrolytic resistance according to DIN ISO 720 that is class HGA 1; and

wherein said glass, apart from unavoidable contaminations, is free of alkali oxides and of magnesium oxide.

2. The pharmaceutical packaging of claim 1 , wherein the ratio (CaO+SrO+BaO)/Al 2 O 3 is smaller than 2.3.

3. The pharmaceutical packaging of claim 1 , wherein the ratio (CaO+SrO+BaO)/Al 2 O 3 is larger than 1.9.

4. The pharmaceutical packaging of claim 1 , wherein the ratio (CaO+SrO+BaO)/SiO 2 >0.25.

5. The pharmaceutical packaging of claim 1 , wherein the content of BaO≤3.

6. The pharmaceutical packaging of claim 1 , wherein the content of Al 2 O 3 is smaller than 12 mol %.

7. The pharmaceutical packaging of claim 1 , wherein the content of Al 2 O 3 is larger than 9 mol %.

8. The pharmaceutical packaging of claim 1 , wherein the content of CaO is larger than 15 mol %.

9. The pharmaceutical packaging of claim 1 , wherein the content of SrO is smaller than 4 mol %.

10. The pharmaceutical packaging of claim 1 , wherein said glass comprises a total content of TiO 2 +ZrO 2 that is at least 0.8 mol %.

11. The pharmaceutical packaging of claim 1 , wherein said glass comprises a total content of TiO 2 +ZrO 2 that is 6 mol % at most.

12. The pharmaceutical packaging of claim 1 , wherein the content of SiO 2 is larger than 60 mol %.

13. The pharmaceutical packaging of claim 1 , wherein the content of SiO 2 is smaller than 70 mol %.

14. The pharmaceutical packaging of claim 1 , wherein the content of:

B 2 O 3 is 0.1-1.

15. The pharmaceutical packaging of claim 1 , wherein said glass has a maximum processing temperature T4 of 1350° C.

16. The pharmaceutical packaging of claim 1 , wherein said glass has a weight loss according to DIN ISO 720 that is smaller than 50 μg Na 2 O/g.

17. The pharmaceutical packaging of claim 1 , wherein said glass further comprises 0.01 to 2 mol % of refining agents.

18. The pharmaceutical packaging of claim 1 , wherein said glass comprises a content of As 2 O 3 , Sb 2 O 3 , Cl—, F— and SO 4 2− that is a maximum of 1.5 mol % each, and wherein the content of SnO 2 and CeO 2 is a maximum of 1 mol % each.

19. The pharmaceutical packaging of claim 1 , wherein said container is at least one container selected from the group consisting of: a bottle, a syringe, a carpule, and an ampoule.

20. A pharmaceutical packaging, comprising a container made of glass and, within said container and in direct contact with said glass, at least one selected from a group consisting of: an active pharmaceutical agent, a buffering solution within a pH-range of 1-11, and water for injection, said glass comprising at least the following components (given in mol % on oxide basis):

SiO 2

59-84

Al 2 O 3

  7-18.5

CaO

 1-25

SrO

  0-6.5

BaO

0-5

ZrO 2

0-3

TiO 2

0-5

B 2 O 3

 0-1,

wherein said glass comprises a ratio (CaO+SrO+BaO)/Al 2 O 3 <2.8;

wherein said glass comprises a ratio (CaO+SrO+BaO)/SiO 2 ≤0.39;

wherein said glass comprises a hydrolytic resistance according to DIN ISO 720 that is class HGA 1; and

wherein said glass, apart from unavoidable contaminations, is free of alkali oxides and of magnesium oxide.